ZA200308857B - Ligands of integrin avbeta6. - Google Patents
Ligands of integrin avbeta6. Download PDFInfo
- Publication number
- ZA200308857B ZA200308857B ZA200308857A ZA200308857A ZA200308857B ZA 200308857 B ZA200308857 B ZA 200308857B ZA 200308857 A ZA200308857 A ZA 200308857A ZA 200308857 A ZA200308857 A ZA 200308857A ZA 200308857 B ZA200308857 B ZA 200308857B
- Authority
- ZA
- South Africa
- Prior art keywords
- biphenyl
- propionic acid
- ethanoylamino
- ureido
- amino
- Prior art date
Links
- 108010044426 integrins Proteins 0.000 title claims description 40
- 102000006495 integrins Human genes 0.000 title claims description 40
- 239000003446 ligand Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 12
- 230000004761 fibrosis Effects 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 7
- 241000193738 Bacillus anthracis Species 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 208000002741 leukoplakia Diseases 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 5
- 230000033115 angiogenesis Effects 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 201000011486 lichen planus Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 201000002793 renal fibrosis Diseases 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 138
- 235000019260 propionic acid Nutrition 0.000 claims 69
- 125000006239 protecting group Chemical group 0.000 claims 19
- 125000003277 amino group Chemical group 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 8
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 claims 6
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 238000011321 prophylaxis Methods 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 206010002329 Aneurysm Diseases 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 241000222122 Candida albicans Species 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 206010014664 Endocardial fibrosis Diseases 0.000 claims 3
- 206010017533 Fungal infection Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 3
- 201000002563 Histoplasmosis Diseases 0.000 claims 3
- 208000037147 Hypercalcaemia Diseases 0.000 claims 3
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 3
- 206010061216 Infarction Diseases 0.000 claims 3
- 206010061217 Infestation Diseases 0.000 claims 3
- 208000031888 Mycoses Diseases 0.000 claims 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 208000027868 Paget disease Diseases 0.000 claims 3
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 3
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 3
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 208000007814 Unstable Angina Diseases 0.000 claims 3
- 206010047249 Venous thrombosis Diseases 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 230000002491 angiogenic effect Effects 0.000 claims 3
- 238000002399 angioplasty Methods 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 210000004204 blood vessel Anatomy 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 229940095731 candida albicans Drugs 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 230000009787 cardiac fibrosis Effects 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 230000035876 healing Effects 0.000 claims 3
- 230000000148 hypercalcaemia Effects 0.000 claims 3
- 210000000987 immune system Anatomy 0.000 claims 3
- 230000007574 infarction Effects 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 208000027202 mammary Paget disease Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 208000001491 myopia Diseases 0.000 claims 3
- 230000004379 myopia Effects 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 230000000010 osteolytic effect Effects 0.000 claims 3
- 210000001672 ovary Anatomy 0.000 claims 3
- 210000000496 pancreas Anatomy 0.000 claims 3
- 230000003071 parasitic effect Effects 0.000 claims 3
- 230000035935 pregnancy Effects 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 201000003068 rheumatic fever Diseases 0.000 claims 3
- 210000000952 spleen Anatomy 0.000 claims 3
- 238000012360 testing method Methods 0.000 claims 3
- 210000001550 testis Anatomy 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 210000001215 vagina Anatomy 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- BEBOOYXCEIYWAE-UHFFFAOYSA-N 3-[[2-[3-[9h-fluoren-9-yl(methoxycarbonyl)amino]propanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1N(C(=O)OC)CCC(=O)NCC(=O)NC(CC(O)=O)C(C=C1)=CC=C1C1=CC=CC=C1 BEBOOYXCEIYWAE-UHFFFAOYSA-N 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 230000002152 alkylating effect Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- FORNGSZIZKIOAV-UHFFFAOYSA-N 3-[[2-[3-(2,2-dimethylpropoxycarbonylamino)propanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C(CC(O)=O)NC(=O)CNC(=O)CCNC(=O)OCC(C)(C)C)=CC=C1C1=CC=CC=C1 FORNGSZIZKIOAV-UHFFFAOYSA-N 0.000 claims 1
- HDQVIEDXLSCTLY-UHFFFAOYSA-N 3-[[2-[3-(carbamoylamino)propanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C(CC(O)=O)NC(=O)CNC(=O)CCNC(=O)N)=CC=C1C1=CC=CC=C1 HDQVIEDXLSCTLY-UHFFFAOYSA-N 0.000 claims 1
- NVTZFZKHGUZGLL-UHFFFAOYSA-N 3-[[2-[3-(methylcarbamothioylamino)propanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C(CC(O)=O)NC(=O)CNC(=O)CCNC(=S)NC)=CC=C1C1=CC=CC=C1 NVTZFZKHGUZGLL-UHFFFAOYSA-N 0.000 claims 1
- GOPRMQWOFVHLCK-UHFFFAOYSA-N 3-[[2-[3-(phenylcarbamoylamino)propanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCNC(=O)NC1=CC=CC=C1 GOPRMQWOFVHLCK-UHFFFAOYSA-N 0.000 claims 1
- XIBWUXBKZILOEV-UHFFFAOYSA-N 3-[[2-[3-[(2,4-dichlorophenyl)methylcarbamoylamino]propanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCNC(=O)NCC1=CC=C(Cl)C=C1Cl XIBWUXBKZILOEV-UHFFFAOYSA-N 0.000 claims 1
- SUVILLQQZAZYRQ-UHFFFAOYSA-N 3-[[2-[3-[(2-methoxyphenyl)carbamoylamino]propanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound COC1=CC=CC=C1NC(=O)NCCC(=O)NCC(=O)NC(CC(O)=O)C1=CC=C(C=2C=CC=CC=2)C=C1 SUVILLQQZAZYRQ-UHFFFAOYSA-N 0.000 claims 1
- YLLHBEGRJOLUTH-UHFFFAOYSA-N 3-[[2-[3-[(3-methoxyphenyl)carbamoylamino]propanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound COC1=CC=CC(NC(=O)NCCC(=O)NCC(=O)NC(CC(O)=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 YLLHBEGRJOLUTH-UHFFFAOYSA-N 0.000 claims 1
- ZLKAUMZYXDOTLM-VGOKPJQXSA-N 3-[[2-[3-[[(1r)-1-phenylethyl]carbamoylamino]propanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound N([C@H](C)C=1C=CC=CC=1)C(=O)NCCC(=O)NCC(=O)NC(CC(O)=O)C(C=C1)=CC=C1C1=CC=CC=C1 ZLKAUMZYXDOTLM-VGOKPJQXSA-N 0.000 claims 1
- ZLKAUMZYXDOTLM-JINQPTGOSA-N 3-[[2-[3-[[(1s)-1-phenylethyl]carbamoylamino]propanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)NCCC(=O)NCC(=O)NC(CC(O)=O)C(C=C1)=CC=C1C1=CC=CC=C1 ZLKAUMZYXDOTLM-JINQPTGOSA-N 0.000 claims 1
- AHCHIUQTVKZCHP-UHFFFAOYSA-N 3-[[2-[4-(2,2-dimethylpropoxycarbonylamino)butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid 3-[[2-[4-(phenylmethoxycarbonylamino)butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1(=CC=C(C=C1)C(CC(=O)O)NC(CNC(CCCNC(=O)OCC(C)(C)C)=O)=O)C1=CC=CC=C1.C1(=CC=C(C=C1)C(CC(=O)O)NC(CNC(CCCNC(=O)OCC1=CC=CC=C1)=O)=O)C1=CC=CC=C1 AHCHIUQTVKZCHP-UHFFFAOYSA-N 0.000 claims 1
- MWYKNZVNTBCAPX-UHFFFAOYSA-N 3-[[2-[4-(benzylcarbamothioylamino)butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCCNC(=S)NCC1=CC=CC=C1 MWYKNZVNTBCAPX-UHFFFAOYSA-N 0.000 claims 1
- UNYXOYAGRAIRDH-UHFFFAOYSA-N 3-[[2-[4-(methylcarbamothioylamino)butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C(CC(O)=O)NC(=O)CNC(=O)CCCNC(=S)NC)=CC=C1C1=CC=CC=C1 UNYXOYAGRAIRDH-UHFFFAOYSA-N 0.000 claims 1
- CYCXCXRZPHMSPZ-UHFFFAOYSA-N 3-[[2-[4-(naphthalen-2-ylcarbamoylamino)butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)NCCCC(=O)NCC(=O)NC(CC(=O)O)C(C=C1)=CC=C1C1=CC=CC=C1 CYCXCXRZPHMSPZ-UHFFFAOYSA-N 0.000 claims 1
- KRVUFJYGNZDMQX-UHFFFAOYSA-N 3-[[2-[4-[(2,4-dichlorophenyl)methylcarbamoylamino]butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCCNC(=O)NCC1=CC=C(Cl)C=C1Cl KRVUFJYGNZDMQX-UHFFFAOYSA-N 0.000 claims 1
- GVPGQRBJNYNACL-UHFFFAOYSA-N 3-[[2-[4-[(2-chlorophenyl)carbamoylamino]butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCCNC(=O)NC1=CC=CC=C1Cl GVPGQRBJNYNACL-UHFFFAOYSA-N 0.000 claims 1
- WVOXYTXZSNRZPC-UHFFFAOYSA-N 3-[[2-[4-[(3-chlorophenyl)carbamoylamino]butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCCNC(=O)NC1=CC=CC(Cl)=C1 WVOXYTXZSNRZPC-UHFFFAOYSA-N 0.000 claims 1
- NVSBXVWWRZKNLL-UHFFFAOYSA-N 3-[[2-[4-[(4-methoxyphenyl)carbamoylamino]butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(OC)=CC=C1NC(=O)NCCCC(=O)NCC(=O)NC(CC(O)=O)C1=CC=C(C=2C=CC=CC=2)C=C1 NVSBXVWWRZKNLL-UHFFFAOYSA-N 0.000 claims 1
- VZCJECIKBDDUIV-UHFFFAOYSA-N 3-[[2-[4-[(4-methoxyphenyl)methylcarbamoylamino]butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(OC)=CC=C1CNC(=O)NCCCC(=O)NCC(=O)NC(CC(O)=O)C1=CC=C(C=2C=CC=CC=2)C=C1 VZCJECIKBDDUIV-UHFFFAOYSA-N 0.000 claims 1
- IISJCRYAOZMILK-UHFFFAOYSA-N 3-[[2-[4-[9h-fluoren-9-yl(methoxycarbonyl)amino]butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1N(C(=O)OC)CCCC(=O)NCC(=O)NC(CC(O)=O)C(C=C1)=CC=C1C1=CC=CC=C1 IISJCRYAOZMILK-UHFFFAOYSA-N 0.000 claims 1
- WCWUKMPRARVWCC-GVNKFJBHSA-N 3-[[2-[4-[[(1s)-1-phenylethyl]carbamoylamino]butanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)NCCCC(=O)NCC(=O)NC(CC(O)=O)C(C=C1)=CC=C1C1=CC=CC=C1 WCWUKMPRARVWCC-GVNKFJBHSA-N 0.000 claims 1
- MOBDZILYQSHWPB-UHFFFAOYSA-N 3-[[2-[5-(butylcarbamoylamino)pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C(CC(O)=O)NC(=O)CNC(=O)CCCCNC(=O)NCCCC)=CC=C1C1=CC=CC=C1 MOBDZILYQSHWPB-UHFFFAOYSA-N 0.000 claims 1
- CSVWKXQHXWXZCS-UHFFFAOYSA-N 3-[[2-[5-(cyclohexylcarbamoylamino)pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCCCNC(=O)NC1CCCCC1 CSVWKXQHXWXZCS-UHFFFAOYSA-N 0.000 claims 1
- NVZJFTCWPVYUPV-UHFFFAOYSA-N 3-[[2-[5-(ethylcarbamoylamino)pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C(CC(O)=O)NC(=O)CNC(=O)CCCCNC(=O)NCC)=CC=C1C1=CC=CC=C1 NVZJFTCWPVYUPV-UHFFFAOYSA-N 0.000 claims 1
- YAAUABTXRZYTTR-UHFFFAOYSA-N 3-[[2-[5-(tert-butylcarbamoylamino)pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C(CC(O)=O)NC(=O)CNC(=O)CCCCNC(=O)NC(C)(C)C)=CC=C1C1=CC=CC=C1 YAAUABTXRZYTTR-UHFFFAOYSA-N 0.000 claims 1
- JKCRZUPLWAECNU-UHFFFAOYSA-N 3-[[2-[5-[(2,4-dichlorophenyl)methylcarbamoylamino]pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCCCNC(=O)NCC1=CC=C(Cl)C=C1Cl JKCRZUPLWAECNU-UHFFFAOYSA-N 0.000 claims 1
- FOEWWOQWEZDZFA-UHFFFAOYSA-N 3-[[2-[5-[(2-chlorophenyl)methylcarbamoylamino]pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCCCNC(=O)NCC1=CC=CC=C1Cl FOEWWOQWEZDZFA-UHFFFAOYSA-N 0.000 claims 1
- MISOODMBKZUPRB-UHFFFAOYSA-N 3-[[2-[5-[(2-methylphenyl)methylcarbamoylamino]pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound CC1=CC=CC=C1CNC(=O)NCCCCC(=O)NCC(=O)NC(CC(O)=O)C1=CC=C(C=2C=CC=CC=2)C=C1 MISOODMBKZUPRB-UHFFFAOYSA-N 0.000 claims 1
- PPUQCIGRRCTZGV-UHFFFAOYSA-N 3-[[2-[5-[(3,4-dichlorophenyl)methylcarbamoylamino]pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCCCNC(=O)NCC1=CC=C(Cl)C(Cl)=C1 PPUQCIGRRCTZGV-UHFFFAOYSA-N 0.000 claims 1
- JGLMIOJGOSNXSW-UHFFFAOYSA-N 3-[[2-[5-[(4-chlorophenyl)carbamoylamino]pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCCCNC(=O)NC1=CC=C(Cl)C=C1 JGLMIOJGOSNXSW-UHFFFAOYSA-N 0.000 claims 1
- USANZMMOEGTYFY-UHFFFAOYSA-N 3-[[2-[5-[(4-fluorophenyl)methylcarbamoylamino]pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(CC(=O)O)NC(=O)CNC(=O)CCCCNC(=O)NCC1=CC=C(F)C=C1 USANZMMOEGTYFY-UHFFFAOYSA-N 0.000 claims 1
- CWKZVJDRRBGDMO-UHFFFAOYSA-N 3-[[2-[5-[(4-methoxyphenyl)carbamoylamino]pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(OC)=CC=C1NC(=O)NCCCCC(=O)NCC(=O)NC(CC(O)=O)C1=CC=C(C=2C=CC=CC=2)C=C1 CWKZVJDRRBGDMO-UHFFFAOYSA-N 0.000 claims 1
- MKFCRTCIWGYEQN-UHFFFAOYSA-N 3-[[2-[5-[9h-fluoren-9-yl(methoxycarbonyl)amino]pentanoylamino]acetyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1N(C(=O)OC)CCCCC(=O)NCC(=O)NC(CC(O)=O)C(C=C1)=CC=C1C1=CC=CC=C1 MKFCRTCIWGYEQN-UHFFFAOYSA-N 0.000 claims 1
- -1 COOA Chemical group 0.000 claims 1
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 claims 1
- 101710095312 Cytosolic 5'-nucleotidase 3A Proteins 0.000 claims 1
- 238000006069 Suzuki reaction reaction Methods 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 150000001499 aryl bromides Chemical class 0.000 claims 1
- 150000007514 bases Chemical class 0.000 claims 1
- 125000005620 boronic acid group Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 7
- 108010021309 integrin beta6 Proteins 0.000 description 6
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 102000007000 Tenascin Human genes 0.000 description 2
- 108010008125 Tenascin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 108700021041 Disintegrin Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001015064 Homo sapiens Integrin beta-6 Proteins 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108010040765 Integrin alphaV Proteins 0.000 description 1
- 102100033011 Integrin beta-6 Human genes 0.000 description 1
- 102000017347 Integrin beta-6 subunit Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000004179 Oral Leukoplakia Diseases 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010039069 anthrax toxin receptors Proteins 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006854 communication Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 102000036072 fibronectin binding proteins Human genes 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000029774 keratinocyte migration Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008557 oral mucosa leukoplakia Diseases 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000012461 sponges Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
- C07C335/08—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
- C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10118550A DE10118550A1 (de) | 2001-04-14 | 2001-04-14 | Liganden des Integrins alpha¶nu¶beta¶6¶ |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200308857B true ZA200308857B (en) | 2004-09-13 |
Family
ID=7681550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200308857A ZA200308857B (en) | 2001-04-14 | 2003-11-13 | Ligands of integrin avbeta6. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040142877A1 (fr) |
EP (1) | EP1379495A2 (fr) |
JP (1) | JP2004528325A (fr) |
KR (1) | KR20030090739A (fr) |
CN (1) | CN1501827A (fr) |
BR (1) | BR0208885A (fr) |
CA (1) | CA2444247A1 (fr) |
CZ (1) | CZ20033000A3 (fr) |
DE (1) | DE10118550A1 (fr) |
HU (1) | HUP0303804A3 (fr) |
MX (1) | MXPA03009318A (fr) |
PL (1) | PL363328A1 (fr) |
RU (1) | RU2003130639A (fr) |
SK (1) | SK13732003A3 (fr) |
WO (1) | WO2002083627A2 (fr) |
ZA (1) | ZA200308857B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
US20090028853A1 (en) * | 2006-10-19 | 2009-01-29 | The Regents Of The University Of California, A California Corporation | TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN ALPHAvBETA6 |
US7838252B2 (en) * | 2005-02-17 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating a subject having an anthrax toxin mediated condition |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
AU2007272995B2 (en) | 2006-07-10 | 2013-02-07 | Biogen Idec Ma Inc. | Compositions and methods for inhibiting growth of smad4-deficient cancers |
WO2014018913A2 (fr) * | 2012-07-27 | 2014-01-30 | University Of Connecticut | Compositions de santacruzamate a et analogues et procédés d'utilisation |
WO2014144466A1 (fr) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anticorps anti-alpha ν bêta 6 et leurs utilisations |
WO2014143739A2 (fr) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anticorps anti-alpha ν bêta 6 et leurs utilisations |
KR102634762B1 (ko) * | 2016-11-01 | 2024-02-06 | 애로우헤드 파마슈티컬스 인코포레이티드 | 알파-v 베타-6 인테그린 리간드 및 그의 용도 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0378167B1 (fr) * | 1989-01-10 | 1994-12-28 | Sumitomo Chemical Company Limited | Composition de colorants dispersés utile pour la teinture ou l'impression de matériaux en fibres hydrophobes |
DE3927069A1 (de) * | 1989-08-16 | 1991-02-21 | Basf Ag | Phenonazofarbstoffe und verfahren zum thermischen transfer dieser farbstoffe |
US5550098A (en) * | 1991-11-14 | 1996-08-27 | Dai Nippon Printing Co., Ltd. | Thermal transfer sheet |
CN1146541C (zh) * | 1999-02-20 | 2004-04-21 | 默克专利股份有限公司 | β-丙氨酸衍生物 |
DE19933173A1 (de) * | 1999-07-15 | 2001-01-18 | Merck Patent Gmbh | Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
-
2001
- 2001-04-14 DE DE10118550A patent/DE10118550A1/de not_active Withdrawn
-
2002
- 2002-03-13 RU RU2003130639/04A patent/RU2003130639A/ru not_active Application Discontinuation
- 2002-03-13 WO PCT/EP2002/002728 patent/WO2002083627A2/fr not_active Application Discontinuation
- 2002-03-13 JP JP2002581384A patent/JP2004528325A/ja active Pending
- 2002-03-13 CA CA002444247A patent/CA2444247A1/fr not_active Abandoned
- 2002-03-13 SK SK1373-2003A patent/SK13732003A3/sk unknown
- 2002-03-13 BR BR0208885-1A patent/BR0208885A/pt not_active Application Discontinuation
- 2002-03-13 HU HU0303804A patent/HUP0303804A3/hu unknown
- 2002-03-13 MX MXPA03009318A patent/MXPA03009318A/es unknown
- 2002-03-13 PL PL02363328A patent/PL363328A1/xx unknown
- 2002-03-13 KR KR10-2003-7013447A patent/KR20030090739A/ko not_active Application Discontinuation
- 2002-03-13 EP EP02747260A patent/EP1379495A2/fr not_active Withdrawn
- 2002-03-13 US US10/474,802 patent/US20040142877A1/en not_active Abandoned
- 2002-03-13 CN CNA028081722A patent/CN1501827A/zh active Pending
- 2002-03-13 CZ CZ20033000A patent/CZ20033000A3/cs unknown
-
2003
- 2003-11-13 ZA ZA200308857A patent/ZA200308857B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR0208885A (pt) | 2004-06-29 |
WO2002083627A3 (fr) | 2003-10-09 |
HUP0303804A2 (hu) | 2004-03-29 |
CA2444247A1 (fr) | 2002-10-24 |
MXPA03009318A (es) | 2004-02-12 |
RU2003130639A (ru) | 2005-04-10 |
CN1501827A (zh) | 2004-06-02 |
DE10118550A1 (de) | 2002-10-17 |
CZ20033000A3 (cs) | 2004-02-18 |
PL363328A1 (en) | 2004-11-15 |
EP1379495A2 (fr) | 2004-01-14 |
JP2004528325A (ja) | 2004-09-16 |
HUP0303804A3 (en) | 2005-09-28 |
SK13732003A3 (sk) | 2004-02-03 |
WO2002083627A2 (fr) | 2002-10-24 |
KR20030090739A (ko) | 2003-11-28 |
US20040142877A1 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200308024B (en) | Inhibitors of integrin alphavbeta6. | |
US5770624A (en) | Certain alpha-substituted arylsulfonamido acetohydroxamic acids | |
US8524907B2 (en) | Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor | |
AU2007271734B2 (en) | Therapeutic compounds | |
NO328151B1 (no) | Benzamider og relaterte inhibitorer for faktor Xa | |
CN1332939C (zh) | 抑制因子Xa活性的新化合物 | |
ZA200308857B (en) | Ligands of integrin avbeta6. | |
AU2003208325B2 (en) | 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin AVSS6 | |
Steplewski et al. | Inhibition of collagen fibril formation | |
Toromanov et al. | Dynamic behavior of vitronectin at the cell–material interface | |
JP2002537287A (ja) | β−アラニン誘導体 | |
JP4546683B2 (ja) | ファクターVIIa阻害剤 | |
AU776797B2 (en) | N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them | |
JPH10512581A (ja) | 血小板凝集阻害剤 | |
JP2003500339A (ja) | インテグリン受容体アンタゴニスト | |
JPS63239256A (ja) | フエニルアラニン誘導体および蛋白分解酵素阻害剤 | |
Schadt et al. | Inhibitors of integrin α ν β 6 | |
CA2238633C (fr) | Acides arylsulfonamidohydroxamiques alpha-substitues comme inhibiteurs du facteur necrosant des tumeurs alpha et des metalloproteinases agissant sur les tissus de support | |
KR20030075322A (ko) | 혈관신생억제제용 설폰아마이드 유도체, 그의 제조방법 및이를 포함하는 약제학적 조성물 |